These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37925471)

  • 1. Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.
    Koiwa F; Sato Y; Ohara M; Nakanishi K; Fukagawa M; Akizawa T
    Sci Rep; 2023 Nov; 13(1):19100. PubMed ID: 37925471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.
    Nakayama M; Kobayashi S; Kusakabe M; Ohara M; Nakanishi K; Akizawa T; Fukagawa M
    Clin Exp Nephrol; 2024 Feb; 28(2):153-164. PubMed ID: 37910313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.
    Akizawa T; Sato Y; Ikejiri K; Kanda H; Fukagawa M
    Kidney Int Rep; 2021 Sep; 6(9):2371-2380. PubMed ID: 34514198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia.
    Nitta K; Itoyama S; Ikejiri K; Kinoshita J; Nakanishi K; Fukagawa M; Akizawa T
    Kidney Int Rep; 2023 Nov; 8(11):2243-2253. PubMed ID: 38025211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Åstrand M; Johansson S; Knutsson M; Langkilde AM; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1933-1942. PubMed ID: 28159782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
    Block GA; Rosenbaum DP; Yan A; Chertow GM
    J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial.
    Inaba M; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Kidney Int Rep; 2022 Feb; 7(2):177-188. PubMed ID: 35155857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Luo H; Feng J; Zhang Y; Wang J; Xue G; Huang X; You S; Dong H; Li L; Li J; Xiao H; Ai X; Li X; Huang B
    Ther Apher Dial; 2023 Oct; 27(5):839-847. PubMed ID: 37349983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
    Block GA; Bleyer AJ; Silva AL; Weiner DE; Lynn RI; Yang Y; Rosenbaum DP; Chertow GM
    Kidney360; 2021 Oct; 2(10):1600-1610. PubMed ID: 35372979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
    Block GA; Rosenbaum DP; Yan A; Greasley PJ; Chertow GM; Wolf M
    Nephrol Dial Transplant; 2019 Feb; 34(2):339-346. PubMed ID: 29617976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenapanor in Chinese ESRD patients with hyperphosphatemia on haemodialysis: a randomised, phase 3 trial.
    Gan L; Xing L; Xu Y; Zhou L; Jiang H; Sun X; Guan T; Luo P; Wang J; Sun F; Guo Z; Guo M; Gao J; Wei G; Zhong W; Zhou Y; Zuo L
    Clin Kidney J; 2024 Jan; 17(1):sfad216. PubMed ID: 38186905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure.
    Hill Gallant KM; Sprague SM; Rosenbaum DP; Spiegel DM; Kozuka K; Edelstein S; Chertow GM
    J Ren Nutr; 2024 Jul; ():. PubMed ID: 38992521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis.
    Yu S; Sun J; Guo X
    Ren Fail; 2024 Dec; 46(2):2410389. PubMed ID: 39351794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
    King AJ; Siegel M; He Y; Nie B; Wang J; Koo-McCoy S; Minassian NA; Jafri Q; Pan D; Kohler J; Kumaraswamy P; Kozuka K; Lewis JG; Dragoli D; Rosenbaum DP; O'Neill D; Plain A; Greasley PJ; Jönsson-Rylander AC; Karlsson D; Behrendt M; Strömstedt M; Ryden-Bergsten T; Knöpfel T; Pastor Arroyo EM; Hernando N; Marks J; Donowitz M; Wagner CA; Alexander RT; Caldwell JS
    Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
    Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
    Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
    King AJ; Kohler J; Fung C; Jiang Z; Quach A; Kumaraswamy P; Chertow GM; Rosenbaum DP
    Am J Physiol Renal Physiol; 2021 Jan; 320(1):F133-F144. PubMed ID: 33283643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
    Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
    J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease.
    Lin T; Al-Makki A; Shepler B
    J Pharm Pharm Sci; 2022; 25():77-83. PubMed ID: 35041802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.